Schedule your COVID-19 vaccine wherever possible. Please do not call your doctor as they cannot schedule an appointment for you. Learn more.

New investigational drug for advanced or metastatic solid tumor cancers

Trial ID:
IRB-20-7578
Darren Sigal, M.D.
The purpose of this open label study is to test the safety and effectiveness of OBI-888 (investigational study drug), given weekly via intravenous infusion (IV), in patients with locally advanced or metastatic solid tumor cancer.

Inclusion Criteria

  • Be 18 yrs of age or older
  • Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light house work, or office work.
  • Have a tissue specimen from a prior biopsy or recent biopsy to be submitted for Globo H analysis

Exclusion Criteria

  • Be pregnant or nursing
  • Have an active autoimmune or inflammatory disease requiring systemic treatment within the past 2Months, or autoimmune disease that requires systemic steroids or other immunosuppressive medications
  • Have a history of solid organ transplant
  • Have known untreated central nervous system disease

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (La Jolla).
  • Study treatment is given weekly by intravenous infusion (IV).
  • Search for NCT03573544 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org